TEVA · Teva Pharmaceutical Industries Ltd - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B | $16.66B |
| Cost of Revenue | $8.32B | $8.48B | $8.20B | $7.95B | $8.28B | $8.93B |
| Gross Profit | $8.94B | $8.06B | $7.64B | $6.97B | $7.59B | $7.73B |
| R&D | $1.01B | $998.00M | $953.00M | $98.00M | $967.00M | $997.00M |
| SG&A | $1.29B | $1.16B | $1.16B | $1.18B | $1.10B | $1.17B |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $1.00B | $1.06B | $1.15B | $1.31B | $1.33B | $1.56B |
| Operating Income | $2.16B | ($303.00M) | $433.00M | ($2.10B) | $1.72B | ($3.57B) |
| Interest Expense | $916.00M | $1.00B | $1.03B | $930.00M | $891.00M | $963.00M |
| Income Tax | ($180.00M) | $676.00M | ($7.00M) | ($638.00M) | $211.00M | ($168.00M) |
| Net Income | $1.41B | ($1.64B) | ($559.00M) | ($2.35B) | $417.00M | ($3.99B) |
| EPS - Basic | $1.23 | ($1.45) | ($0.50) | ($2.12) | $0.38 | ($3.64) |
| EPS - Diluted | $1.21 | ($1.45) | ($0.50) | ($2.12) | $0.38 | ($3.64) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.56B | $3.30B | $3.23B | $2.80B | $2.17B | $2.18B |
| Accounts Receivable | $3.71B | $3.06B | $3.41B | $3.70B | $4.53B | $4.58B |
| Inventory | $3.18B | $3.01B | $4.02B | $3.83B | $3.82B | $4.40B |
| Accounts Payable | $225.00M | $108.00M | $2.60B | $1.89B | $1.69B | $1.76B |
| Current Assets | $13.95B | $12.55B | $12.48B | $12.05B | $12.57B | $13.01B |
| Total Assets | $40.75B | $39.33B | $43.48B | $44.01B | $47.67B | $50.64B |
| Current Liabilities | $13.46B | $12.80B | $12.25B | $11.47B | $11.03B | $13.16B |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $32.83B | $33.61B | $35.35B | $35.31B | $36.42B | $39.58B |
| Stockholders' Equity | $7.91B | $5.37B | $7.51B | $7.90B | $10.28B | $10.03B |
| Retained Earnings | ($13.76B) | ($15.17B) | ($13.53B) | ($12.88B) | ($10.53B) | ($10.95B) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.65B | $1.25B | $1.37B | $1.59B | $798.00M | $1.22B |
| Investing Cash Flow | $737.00M | $792.00M | $968.00M | $656.00M | $1.52B | $863.00M |
| Financing Cash Flow | ($2.15B) | ($1.79B) | ($1.91B) | ($1.49B) | ($2.17B) | ($1.89B) |
| CapEx | $501.00M | $498.00M | $526.00M | $548.00M | $562.00M | $578.00M |
| Free Cash Flow | $1.15B | $749.00M | $842.00M | $1.04B | $236.00M | $638.00M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 51.8% | 48.7% | 48.2% | 46.7% | 47.8% | 46.4% |
| Operating margin | 12.5% | -1.8% | 2.7% | -14.1% | 10.8% | -21.4% |
| EBITDA margin | 18.3% | 4.6% | 10.0% | -5.3% | 19.2% | -12.1% |
| Net margin | 8.2% | -9.9% | -3.5% | -15.8% | 2.6% | -24.0% |
| Free cash flow margin | 6.7% | 4.5% | 5.3% | 7.0% | 1.5% | 3.8% |
| FCF / Net income | 0.81 | -0.46 | -1.51 | -0.44 | 0.57 | -0.16 |
| R&D / Revenue | 5.9% | 6.0% | 6.0% | 0.7% | 6.1% | 6.0% |
| SG&A / Revenue | 7.5% | 7.0% | 7.3% | 7.9% | 6.9% | 7.0% |
| Effective tax rate | -14.6% | - | - | - | 33.6% | - |
| Return on assets | 3.5% | -4.2% | -1.3% | -5.3% | 0.9% | -7.9% |
| Return on equity | 17.8% | -30.5% | -7.4% | -29.8% | 4.1% | -39.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.04 | 0.98 | 1.02 | 1.05 | 1.14 | 0.99 |
| Quick ratio | 0.80 | 0.75 | 0.69 | 0.72 | 0.79 | 0.65 |
| Cash ratio | 0.26 | 0.26 | 0.26 | 0.24 | 0.20 | 0.17 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 2.4x | -0.3x | 0.4x | -2.3x | 1.9x | -3.7x |
| Equity multiplier | 5.15 | 7.32 | 5.79 | 5.57 | 4.64 | 5.05 |
| Liabilities / Assets | 0.81 | 0.85 | 0.81 | 0.80 | 0.76 | 0.78 |
| Efficiency | ||||||
| Asset turnover | 0.42 | 0.42 | 0.36 | 0.34 | 0.33 | 0.33 |
| Inventory turnover | 2.62 | 2.82 | 2.04 | 2.07 | 2.17 | 2.03 |
| Days sales outstanding | 78d | 67d | 79d | 90d | 104d | 100d |
| Days inventory outstanding | 139d | 129d | 179d | 176d | 168d | 180d |
| Days payable outstanding | 10d | 5d | 116d | 87d | 74d | 72d |
| Cash conversion cycle | 208d | 192d | 142d | 180d | 198d | 209d |
| Valuation | ||||||
| P / E | 25.8x | - | - | - | 21.1x | - |
| P / B | 4.6x | 4.6x | 1.6x | 1.3x | 0.9x | 1.1x |
| P / S | 2.1x | 1.5x | 0.7x | 0.7x | 0.6x | 0.6x |
| EV / EBITDA | 10.4x | 28.6x | 5.3x | - | 2.2x | - |
| Growth | ||||||
| Revenue growth (YoY) | 4.3% | 4.4% | 6.2% | -6.0% | -4.7% | -1.4% |
| Revenue CAGR (3y) | 5.0% | 1.4% | -1.7% | -4.0% | -10.8% | - |
| Revenue CAGR (5y) | 0.7% | -0.4% | -6.7% | - | - | - |
| Gross profit growth (YoY) | 10.8% | 5.5% | 9.6% | -8.2% | -1.7% | 2.5% |
| Operating income growth (YoY) | - | - | - | - | - | -706.3% |
| Net income growth (YoY) | - | -193.2% | 76.2% | - | - | -299.4% |
| EPS growth (YoY) | - | -190.0% | 76.4% | - | - | -300.0% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 53.3% | -11.0% | -19.2% | 341.5% | -63.0% | 186.1% |
| FCF CAGR (5y) | 12.5% | 27.4% | -14.0% | - | - | - |
| Book value growth (YoY) | 47.2% | -28.4% | -5.0% | -23.2% | 2.5% | -28.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$17.26B totalUnited States Segment$9.19B · 53.2%
Europe Segment$5.04B · 29.2%
International Markets$2.16B · 12.5%
Other Activities$870.00M · 5.0%
Product / service
$18.60B totalProduct$7.08B · 38.1%
Generics Medicians Including Otc And Biosimilars$3.66B · 19.7%
Austedo$2.22B · 11.9%
Anda$1.50B · 8.0%
Distribution Service$1.50B · 8.0%
Other Products$929.00M · 5.0%
License$607.00M · 3.3%
Ajovy$295.00M · 1.6%
COPAXONE$255.00M · 1.4%
Respiratory Product$227.00M · 1.2%
Uzedy$191.00M · 1.0%
Bendeka And Treanda$147.00M · 0.8%
Product And Service Other$2.00M · 0.0%
Geographic
$14.23B totalUS$9.19B · 64.6%
Europe$5.04B · 35.4%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.41
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
7/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing TEVA PHARMACEUTICAL INDUSTRIES LTD against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Nov 27, 2017 | $0.0850 |
| Aug 25, 2017 | $0.0850 |
| Jun 1, 2017 | $0.3400 |
| Feb 28, 2017 | $0.3400 |
| Dec 1, 2016 | $0.3400 |
| Aug 18, 2016 | $0.3400 |
| May 20, 2016 | $0.3400 |
| Feb 25, 2016 | $0.3400 |
| Nov 13, 2015 | $0.3400 |
| Aug 18, 2015 | $0.3400 |
| May 15, 2015 | $0.3400 |
| Feb 17, 2015 | $0.3400 |
| Nov 13, 2014 | $0.3210 |
| Aug 19, 2014 | $0.3530 |
| May 16, 2014 | $0.3470 |
| Feb 20, 2014 | $0.3450 |
| Nov 18, 2013 | $0.3260 |
| Aug 16, 2013 | $0.3220 |
| May 16, 2013 | $0.3200 |
| Feb 19, 2013 | $0.3100 |
| Nov 13, 2012 | $0.2570 |
| Aug 13, 2012 | $0.2490 |
| May 17, 2012 | $0.2610 |
| Feb 23, 2012 | $0.2670 |